Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Drug interactions between Ibrance and Neupogen

Results for the following 2 drugs:
Ibrance (palbociclib)
Neupogen (filgrastim)

Interactions between your drugs

Moderate

filgrastim palbociclib

Applies to: Neupogen (filgrastim) and Ibrance (palbociclib)

Using filgrastim during or too soon after completion of a course of palbociclib may alter the effects of either medication. Filgrastim should generally not be given within 24 hours before or 24 hours after cancer chemotherapy. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Drug and food interactions

Moderate

palbociclib food

Applies to: Ibrance (palbociclib)

Palbociclib should be taken with food to help with its absorption. Do not consume grapefruit or grapefruit juice during treatment with palbociclib unless directed otherwise by your doctor. Grapefruit juice can increase the blood levels of palbociclib. You may be more likely to experience side effects such as nausea; vomiting; diarrhea; loss of appetite; mouth sores; hair loss; weakness; pain, numbness, or tingling in the hands and feet; and impaired bone marrow function resulting in low numbers of different types of blood cells, which can increase the risk of anemia, bleeding problems, and infections. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No therapeutic duplications were found for your selected drugs.

Drug Interaction Classification

The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide